Biosensors for breast cancer diagnosis: A review of bioreceptors, biotransducers and signal amplification strategies

Mittal, Sunil; Kaur, Hardeep; Gautam, Nandini; Mantha, Anil K.

doi:10.1016/j.bios.2016.08.028

Cited by 254 publications

(116 citation statements)

References 176 publications

Supporting

Mentioning

112

Contrasting

Unclassified

Order By: Relevance

“…On the other hand, cytokeratin fragment 21‐1 (CYFRA 21‐1), squamous cell carcinoma antigen (SCC) and carcinoembryonic antigen (CEA) have been associated with NSCLC cases, which represent the vast majority of lung cancer cases ; (ii) Breast cancer is a healthcare concern of women worldwide. The protein biomarkers with evidence of clinical utility for breast cancer include CEA, Human epidermal growth factor receptor 2 (HER2) and Cancer Antigen 15‐3 (CA 15‐3) ; (iii) Colorectal cancer (CRC) is the second most commonly diagnosed cancer among women and third among men worldwide. Two of the most widely known serum protein biomarkers for CRC are the Cancer Antigen 19‐9 (CA 19‐9) and CEA.…”

Section: Cancer Biomarkersmentioning

confidence: 99%

Electrochemical Biosensing in Cancer Diagnostics and Follow‐up

2018

View full text Add to dashboard Cite

In cancer, screening and early detection are critical for the success of the patient's treatment and to increase the survival rate. The development of analytical tools for non‐invasive detection, through the analysis of cancer biomarkers, is imperative for disease diagnosis, treatment and follow‐up. Tumour biomarkers refer to substances or processes that, in clinical settings, are indicative of the presence of cancer in the body. These biomarkers can be detected using biosensors, that, because of their fast, accurate and point of care applicability, are prominent alternatives to the traditional methods. Moreover, the constant innovations in the biosensing field improve the determination of normal and/or elevated levels of tumour biomarkers in patients’ biological fluids (such as serum, plasma, whole blood, urine, etc.). Although several biomarkers (DNA, RNA, proteins, cells) are known, the detection of proteins and circulating tumour cells (CTCs) are the most commonly reported due to their approval as tumour biomarkers by the specialized entities and commonly accepted for diagnosis by medical and clinical teams. Therefore, electrochemical immunosensors and cytosensors are vastly described in this review, because of their fast, simple and accurate detection, the low sample volumes required, and the excellent limits of detection obtained. The biosensing strategies reported for the six most commonly diagnosed cancers (lung, breast, colorectal, prostate, liver and stomach) are summarized and the distinct phases of the sensors’ constructions (surface modification, antibody immobilization, immunochemical interactions, detection approach) and applications are discussed.

show abstract

Section: Cancer Biomarkersmentioning

confidence: 99%

Electrochemical Biosensing in Cancer Diagnostics and Follow‐up

2018

View full text Add to dashboard Cite

show abstract

“…Nevertheless, the evolution of clinical methods for effective detection of breast cancer along with the development of non-invasive and low-cost in situ techniques can improve survival rates and allow personalized patient follow-up [2,4]. Breast cancer biomarkers can be divided into prognostic, therapeutic and diagnostic, and can be detected according to the stage of the cancer [7]. For this purpose, biosensors have been developed because they provide fast analysis and specific recognition.…”

Section: Introductionmentioning

confidence: 99%

“…For this purpose, biosensors have been developed because they provide fast analysis and specific recognition. HER2 is overexpressed in 20-30 % of invasive breast cancer and HER2-positive breast cancer is particularly more aggressive than others [7][8][9]. Current innovations in the field of biosensing lead to accurate results in the analysis of tumour biomarkers in patients' biological fluids such as serum, plasma, whole blood, urine, etc.…”

Section: Introductionmentioning

confidence: 99%

Electrochemical Sensing Platforms for HER2‐ECD Breast Cancer Biomarker Detection

2018

View full text Add to dashboard Cite

Screening and early diagnosis are crucial to increase the success of cancer patients’ treatments and improve the survival rate. To contribute to this success, distinct electrochemical immunosensing platforms were developed for the analysis of the ExtraCellular Domain of the Human Epidermal growth factor Receptor 2 (HER2‐ECD) through sandwich assays on nanomaterial‐modified screen‐printed carbon electrodes (SPCEs). The most promising platforms showed to be SPCEs modified with (i) gold nanoparticles (AuNPs) and (ii) multiwalled carbon nanotubes combined with AuNPs. The antibody‐antigen interaction was detected using a secondary antibody labelled with alkaline phosphatase and 3‐indoxyl phosphate and silver ions as the enzymatic substrate. The electrochemical signal of the enzymatically generated metallic silver was recorded by linear sweep voltammetry. Under the optimized conditions, linear calibration plots were obtained between 7.5 and 50 ng/mL and the total assay time was 2 h 20 min, achieving LODs of 0.16 ng/mL (SPCE‐MWCNT/AuNP) and 8.5 ng/mL (SPCE‐AuNP), which are well below the established cut‐off value of 15 ng/mL for this cancer biomarker.

show abstract

“…Therefore, biosensors for various biomarkers, pathogens, or physiological signal detections are preferred for rapid clinical testing. [4][5][6] The main limitation of typical blood tests is that relatively high volumes (in mL) of blood samples, relatively long analysis times (>1 h), and complicated processing steps are required. [7] Moreover, the reliability of testing results depends on the quality of plasma.…”

Section: Introductionmentioning

confidence: 99%

Thermopneumatic suction integrated microfluidic blood analysis system

Yang

Hsieh

Tsou

et al. 2018

Preprint

View full text Add to dashboard Cite

Blood tests provide crucial diagnostic information regarding several diseases. A key factor that affects the precision and accuracy of blood tests is the interference of red blood cells; however, the conventional methods of blood separation are often complicated and time consuming. In this study, we devised a simple but high-efficiency blood separation system on a self-strained microfluidic device that separates 99.7% of the plasma in only 6 min. Parameters, such as flow rate, design of the filter trench, and the relative positions of the filter trench and channel, were optimized through microscopic monitoring. Moreover, this air-difference-driven device uses a cost-effective and easy-to-use heater strip that creates a low-pressure environment in the microchannel within minutes. With the aforementioned advantages, this blood separation device could be another platform choice for point-of-care testing.

show abstract

Biosensors for breast cancer diagnosis: A review of bioreceptors, biotransducers and signal amplification strategies

Cited by 254 publications

References 176 publications

Electrochemical Biosensing in Cancer Diagnostics and Follow‐up

Electrochemical Biosensing in Cancer Diagnostics and Follow‐up

Electrochemical Sensing Platforms for HER2‐ECD Breast Cancer Biomarker Detection

Thermopneumatic suction integrated microfluidic blood analysis system

Contact Info

Product

Resources

About